Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ketanserin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Ketanserin: Sponsors, patents, clinical trial progress

Ketanserin is an investigational drug.

There have been 7 clinical trials for Ketanserin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Diabetic Foot, Shock, Septic, and Sepsis. The leading clinical trial sponsors are Gitte Moos Knudsen, Cell Pharma, SA de CV, and Psychiatric University Hospital, Zurich.

There is one US patent protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for Ketanserin
Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)Matthias LiechtiEarly Phase 1
The Neurobiological Effect of 5-HT2AR ModulationGitte Moos KnudsenPhase 1
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy VolunteersPsychiatric University Hospital, ZurichN/A

See all Ketanserin clinical trials

Clinical Trial Summary for Ketanserin

Top disease conditions for Ketanserin
Top clinical trial sponsors for Ketanserin

See all Ketanserin clinical trials

US Patents for Ketanserin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ketanserin   Start Trial Determining a modal amplitude of an inhomogeneous field with a quantum sensor THE UNITED STATES OF AMERCA, AS REPRESENTED BY THE SECRETARY OF COMMERCE (Washington, DC)   Start Trial
Ketanserin   Start Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder Axovant Sciences GmbH (Basel, CH)   Start Trial
Ketanserin   Start Trial Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent Johnson & Johnson Consumer Inc. (Skillman, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.